Carasent Ab · OMXSTO:CARA
Carasent Ab — Q3 2026 Earnings Presentation
16 slides from Carasent Ab's earnings presentation, Oct 15, 2026
Slide 1: Interim report Q3
Interim report Q3 15 October 2026 Driving efficiency and quality in the world of care
Slide 2: Agenda
Agenda Todays presenters 1 Company update 2 Financial update Daniel Öhman Svein Martin Bjørnstad CEO CFO
Slide 3: Fast growing and highly recurring EHR business
Fast growing and highly recurring EHR business 3 390 LTM quarterly revenue 364 SEKm Rapidly improving financials 344 349 329 311 275 294 424m 14% 25% 245 250 254 261 240 Contracted ARR Organic ARR EBITDA margin 233 Q3 2026 growth Q3 2026 220 195 179 168 154 Sticky SaaS business model 137 128 >90% 3%
Slide 4: Highlights Q3
Highlights Q3 4 Update ▪ Strong sales to both new customers and add-on services, including Falck Norway and Frelsesarmeen ▪ Infosolutions developing strongly ▪ Germany entering a new phase Growth ▪ Contracted ARR of SEK 424m, 29% growth YoY ▪ 14% organic ARR growth and 12% organic revenue growth Pro
Slide 5: Medsum – strong traction
Medsum – strong traction 5 Adoption Key metrics ▪ Medsum, our AI assistant, automatically drafts clinical notes Medsum users per month from the patient consultation ▪ Close to 400 active users at the end of September ▪ Around 300 paying users, up from 13 in January ▪ Customers are satisfied and repo
Slide 6: Medsum AI assistant screenshot
ae Men fir virdennet = Webdoc Testklinik & Tolvan Tolvansson + Lagg till favoriter Huvudcontent +4 Al-Assistenten 9 @~ @ Kinsvensson Journaléversikt Al-Assistenten Inspelning Inspelning pagar Patient: Tolvan Tolvansson (19121212-1212) ‘Stoppa inspelning aj Inspelningar Inspelning 1 Inspelning 2 Insp
Slide 7: AI assistant identified actions screenshot
= Meny for virdenhet = Webdoc Testklinik & Tolvan Tolvansson + Lagg til favoriter Huvudcontent 9 @~ | O kinsvensson €D > + Al-Assistenten journaléve Al-Assistenten Inspelning —_Historik I stoppa inspeining 00:32 Attgora @ jt Inspelningar 4 © Al-identifierade atgarder fran samtalet VU Lakarintyg till
Slide 8: Germany: behind plan, stepping up
Germany: behind plan, stepping up 8 Where we are Key metrics ▪ Revenue down 10% yoy due to higher churn EBITDAC margin Q3 2026 ▪ Webcur launch delayed, slower ramp-up than planned 25% ▪ Reduced group adj. EBITDAC by ~SEK 3m in Q3 20% Why we believe in Germany ▪ Large fragmented market with huge pote
Slide 9: Journey Ahead
Journey Ahead 9 Strong organic growth Efficient use of resources Launch Webcur Strong foundation of mission critical solutions with minimal churn in a growing and non-cyclical industry
Slide 10: Financial update
€3 CARASENT Financial update Q3 2026
Slide 11: Carasent – Q3 financial highlights
Carasent – Q3 financial highlights 11 424 14% 25% Million contracted ARR per Q3 Organic ARR growth EBITDA margin 2026 (constant fx) 29% 110% 20% ARR growth Net retention rate EBITDAC margin
Slide 12: Strong improvements YoY
Strong improvements YoY 12 SEKm Q3 2026 Q3 2025 YoY growth YTD 2026 YTD 2025 1▪ 32% revenue growth, 12% organic growth Subscription based 84.4 67.2 26 % 234.2 196.9 Transaction based 14.0 10.3 36 % 41.9 33.9 Consulting and other 9.7 4.7 106 % 20.1 19.4 2▪ InfoSolutions dilutes gross margin slightly
Slide 13: 14% organic ARR growth
14% organic ARR growth 13 Ending Q3 at a good pace with 14% organic ARR growth Implemented ARR Signed, not implemented ARR 424 8 44 380 8 9 13 339 42 12 +4% -3% +13% 416 14% 373 Q325 ARR Net upsale Churn New customers Q3’26 ARR organic M&A Q3’26 ARR (constant currency)
Slide 14: Scalability over time
Scalability over time 14 Keeping costs flat while growing revenues LTM development of cash cost base (adjusted for one-offs) LTM Revenue: 390m 245 243 236 231 231 229 229 234 234 231 229 229 232 Flat cost base Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3
Slide 15: Working capital seasonally weak
Working capital seasonally weak 15 SEKm Q3 2026 Q3 2025 YTD 2026 YTD 2025 ▪ Seasonally weak Q3, strong cash flow YTD: Revenue 108.2 82.2 296.3 250.3 ▪ Operating cash flow of SEK 5m, Reported EBITDA 27.5 23.6 60.5 49.6 working capital SEK -22m (Q3 Change in working capital -22.0 -21.1 13.2 -29.7 2025
Slide 16: Q&A
Q&A